- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Hemophagocytic lymphohistiocytosis.
Displaying page 1 of 1.
EudraCT Number: 2014-005585-30 | Sponsor Protocol Number: P120109 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003114-10 | Sponsor Protocol Number: NI-0501-09 | Start Date*: 2018-09-06 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AG | |||||||||||||
Full Title: An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life... | |||||||||||||
Medical condition: Primary Hemophagocytic Lymphohistiocytosis (pHLH) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002391-17 | Sponsor Protocol Number: HLH-2004 | Start Date*: 2005-03-10 | |||||||||||
Sponsor Name:AZIENDA DI RILIEVO NAZIONALE E DI ALTA SPECIALIZZAZIONE OSPEDALE CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI | |||||||||||||
Full Title: Treatment protocol of the second international study for hemophagoocytic lymphohistiocytosis (HLH) | |||||||||||||
Medical condition: Hemophagocytic lymphohistiocytosis (HLH) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001577-24 | Sponsor Protocol Number: NI-0501-14 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AG (Sobi AG) | |||||||||||||
Full Title: A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage ac... | |||||||||||||
Medical condition: Macrophage activation syndrome (MAS) in the context of Systemic juvenile inflammatory arthritis (sJIA) and Adult onset Still’s disease (AOSD). MAS in the context of pediatric and adult Systemic lup... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) IT (Trial now transitioned) PL (Completed) DE (Completed) CZ (Trial now transitioned) BE (Completed) SE (Completed) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002428-36 | Sponsor Protocol Number: RG_19-271 | Start Date*: 2020-12-02 | |||||||||||||||||||||
Sponsor Name:University of Birmingham | |||||||||||||||||||||||
Full Title: A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or relapsed/refractory solid tumours | |||||||||||||||||||||||
Medical condition: Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) and relapsed/refractory solid tumours | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005753-23 | Sponsor Protocol Number: NI-0501-05 | Start Date*: 2013-06-19 | |||||||||||
Sponsor Name:NovImmune SA | |||||||||||||
Full Title: A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. | |||||||||||||
Medical condition: haemophagocytic lymphohistiocytosis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) DE (Completed) ES (Completed) AT (Completed) SE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002052-14 | Sponsor Protocol Number: EURO-HIT-HLH | Start Date*: 2011-06-07 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA MEYER | |||||||||||||
Full Title: EURO-HIT-HLH European cooperative pilot study for testing Hybrid ImmunoTherapy for Hemophagocytic LymphoHistiocytosis | |||||||||||||
Medical condition: Familial hemophagoytic lymphohistiocytosis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003279-18 | Sponsor Protocol Number: HLH-2004 | Start Date*: Information not available in EudraCT |
Sponsor Name:Barncancerforskningsenheten, Astrid Lindgrens Barnsjukhus | ||
Full Title: HLH-2004. Hemophagocytic Lymphohistiocytosis Study Group. Treatment Protocol of the Second International HLH Study 2004. | ||
Medical condition: Hemophagocytic Lymphohistiocytosis (HLH), a life-threatening disease usually occurring in early childhood. HLH-2004 is an international treatment protocol which will be compared with the previous ... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002483-31 | Sponsor Protocol Number: UZBRU_VHH2_2 | Start Date*: 2020-11-30 |
Sponsor Name:UZ Brussel | ||
Full Title: Phase II study to evaluate the clinical potential of 68GaNOTA-Anti-MMR-VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in oncological lesions, ... | ||
Medical condition: C1: malignancies of the head and neck. C2: malignancy with a solid component C3: carotid plaque, planned for (SOC) carotid endarterectomy. C4: biopsy-proven Hodgkin or non-Hodgkin lymphoma. C5: su... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003632-23 | Sponsor Protocol Number: NI-0501-04 | Start Date*: 2016-02-24 | |||||||||||
Sponsor Name:NovImmune SA | |||||||||||||
Full Title: A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... | |||||||||||||
Medical condition: Haemophagocytic lymphohistiocytosis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) AT (Completed) CZ (Completed) DE (Completed) ES (Prematurely Ended) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000407-20 | Sponsor Protocol Number: APHP201454 | Start Date*: 2021-09-22 |
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS | ||
Full Title: Treatment of nonsevere sporadic Hemophagocytosis Lymphohistiocytosis (HLHs) with ITACITINIB: a phase II prospective trial. | ||
Medical condition: Adults patients having non severe sporadic Hemophagocytosis Lymphohistiocytosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004223-23 | Sponsor Protocol Number: NI-0501-06 | Start Date*: 2017-04-14 | |||||||||||
Sponsor Name:Novimmune SA | |||||||||||||
Full Title: A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) mo... | |||||||||||||
Medical condition: Macrophage activation syndrome / Secondary hemophagocytic lymphohistiocytosis (MAS/sHLH) in patients with Systemic Juvenile Idiopathic Arthritis (sJIA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001963-10 | Sponsor Protocol Number: 2020-CHITS-003 | Start Date*: 2020-05-12 |
Sponsor Name:Centre Hospitalier Intercommunal de Toulon La Seyne-sur-mer | ||
Full Title: Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation: Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib | ||
Medical condition: Covid-19 disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002119-23 | Sponsor Protocol Number: IEO1253 | Start Date*: 2020-11-16 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: COVitaminD Trial: prevention of complications from COVID-19 in cancer patients under active treatment | |||||||||||||
Medical condition: Oncological patients in active oncological treatment diagnosed with Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000177-25 | Sponsor Protocol Number: ATA129-EBV-205 | Start Date*: 2021-01-04 | |||||||||||
Sponsor Name:Atara Biotherapeutics, Inc. | |||||||||||||
Full Title: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases | |||||||||||||
Medical condition: • EBV+ primary imunodeficiency lymphoproliferative disease (LPD) • EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency • EBV+ post-transplant LPD involving the central nervous ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001387-20 | Sponsor Protocol Number: ELA026-CP002 | Start Date*: 2021-10-11 | ||||||||||||||||
Sponsor Name:Electra Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymph... | ||||||||||||||||||
Medical condition: sHLH is a rare and life-threatening inflammatory syndrome characterized by dysregulated immune function. The disease is associated with a massive systemic inflammatory response for which patients r... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003409-23 | Sponsor Protocol Number: MERMAID1 | Start Date*: 2023-12-12 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. Phase I/I... | |||||||||||||
Medical condition: B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000516-37 | Sponsor Protocol Number: TS-020DESE | Start Date*: 2021-03-04 | |||||||||||
Sponsor Name:TurnSole Biologics Llc | |||||||||||||
Full Title: A Phase I/II open-label study for Azacitidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20–50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients ... | |||||||||||||
Medical condition: COVID-19 patients with confirmed sever viral infection of SARS-COV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003884-71 | Sponsor Protocol Number: LPS13649 | Start Date*: 2015-02-05 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
